MedPath

Chlorotrianisene

Generic Name
Chlorotrianisene
Drug Type
Small Molecule
Chemical Formula
C23H21ClO3
CAS Number
569-57-3
Unique Ingredient Identifier
6V5034L121

Overview

A powerful synthetic, non-steroidal estrogen. [PubChem]

Indication

Used to treat symptoms of menopause, deficiencies in ovary function (including underdevelopment of female sexual characteristics and some types of infertility), and in rare cases, prostate cancer. Chlorotrianisene may also be used to prevent breast engorgement following childbirth.

Associated Conditions

No associated conditions information available.

Clinical Trials

Title
Posted
Study ID
Phase
Status
Sponsor
Single-arm Clinical Trial of TACE in Combination With Acoradine as Adjuvant Therapy After Surgery in Patients With Hepatocellular Carcinoma at High Risk of Recurrence
2024/10/16
NCT06644937
Phase 2
Not yet recruiting
Zhujiang Hospital
Efficacy, Safety, and Treatment Patterns of Transcatheter Arterial Chemoembolization (TACE) Combined With Atezolizumab and Bevacizumab in Unresectable Hepatocellular Carcinoma: a Multicenter, Retrospective, Observational Real-world Study
2023/09/06
NCT06024252
N/A
Not yet recruiting
Zhongda Hospital
Single Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocellular Carcinoma
2023/08/01
NCT05970666
Phase 2
Recruiting
The First Affiliated Hospital of Xiamen University
TACE Combined With Lenvatinib and MWA in the Treatment of Locally Advanced Large Hepatocellular Carcinoma
2022/09/26
NCT05555316
Phase 2
Recruiting
Sun Yat-sen University
An Exploratory Study of Sequential Transarterial Chemoembolization With Lipiodol and Neoadjuvant Chemotherapy in the Treatment of Initial Unresectable Colorectal Cancer (CRC)
2022/04/22
NCT05340231
Phase 2
Not yet recruiting
Gang Wu
A Study to Evaluate TACE Sequential Tislelizumab as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection
2021/07/29
NCT04981665
Phase 2
Recruiting
Zhejiang University
Perioperative Therapy for Hepatocellular Carcinoma
2020/12/04
NCT04653389
Phase 2
Terminated
Zhejiang University
TACE Combined With Sorafenib and Tislelizumab for Advanced HCC
2020/10/23
NCT04599777
Phase 2
Completed
Second Affiliated Hospital of Guangzhou Medical University
TACE Combined With Lenvatinib and Sintilimab for Advanced HCC
2020/10/23
NCT04599790
Phase 2
Completed
Second Affiliated Hospital of Guangzhou Medical University
TACE Combined With Sintilimab and Bevacizumab for Unresectable HCC
2020/10/19
NCT04592029
Phase 1
UNKNOWN
Second Affiliated Hospital of Guangzhou Medical University

FDA Drug Approvals

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
Chlorotrianisene Pills
苏州第壹制药有限公司
国药准字H32023059
化学药品
滴丸剂
8/11/2020

PPB Drug Approvals

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product
ARTG ID
Sponsor
Registration Type
Status
Registration Date
No TGA approvals found for this drug.

Help Us Improve

Your feedback helps us provide better drug information and insights.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.